| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e75810cb7d022e16fc3e012a68ae090 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B20-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-483
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate |
2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d67612e9fd779ced4ab31d8b6ad4bba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92fab36adfc98a4dc89ff9666c28c082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_277ffabcb41d42d3660c794edd6337d9 |
| publicationDate |
2020-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-3054640-A1 |
| titleOfInvention |
Prognosis and treatment of relapsing leukemia |
| abstract |
Described are biomarkers and associated methods for determining a prognosis for a subject with leukemia and/or for detecting Leukemic Regenerating Cells (LRCs) or Hematopoietic Regenerating Cells. While chemotherapy may successfully deplete leukemic stem cells (LSCs), a molecularly distinct population of LRCs are observed following cytotoxic chemotherapy not seen in therapy naïve subjects with leukemia or healthy hematopoietic cell populations. Also described are methods for the treatment of leukemia that target LRCs in a subject in need thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113063944-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113063944-B |
| priorityDate |
2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |